Pantarotto, MarcosBarata, RitaCoelho, RicardoSousa, VirginiaCarvalheiro, CatarinaRolim, InesGarrido, PatriciaGIl, NunoDuarte-Ramos, FilipaTonin, Fernanda2023-02-282023-02-282023-02Pantarotto M, Barata R, Coelho R, Cavalheiro C, Rolim I, Tonin FS, et al. Correction: The meaning of lymphadenopathies during adjuvant durvalumab after chemoradiotherapy for lung cancer: thinking beyond disease progression. Cureus. 2023;15(2):c101.http://hdl.handle.net/10400.21/15726This article has been corrected at the request of the authors to include Virginia Sousa as the fourth author as she was erroneously omitted during the submission process. The authors deeply regret that this error was not identified and addressed prior to publication.engImmune-checkpoint inhibitorsPseudoprogressionImmune-related adverse eventsLung cancerDifferential diagnosisjournal article10.7759/cureus.c101